Novartis
3 October 2019Big PharmaRory O'Neill
Novartis and Microsoft to collaborate on AI in medicine
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.
Big Pharma
17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.
Editor's picks
Editor's picks
Big Pharma
21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.
Big Pharma
17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.
Big Pharma
21 January 2019 Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.
Big Pharma
17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.